WP
HRTX icon

Woodline Partners’s Heron Therapeutics HRTX Stock Holding History

Woodline Partners’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-569,212
Closed -$860K – 690
2023
Q1 		$860K Hold
569,212
– – 0.01% 485
2022
Q4 		$1.42M Sell
569,212
-228,694
-29% -$737K 0.02% 517
2022
Q3 		$3.37M Sell
797,906
-20,256
-2% -$79.3K 0.05% 367
2022
Q2 		$2.28M Buy
818,162
+249,007
+44% +$1,000K 0.04% 407
2022
Q1 		$3.26M Buy
569,155
+11,356
+2% +$83.1K 0.05% 301
2021
Q4 		$5.09M Buy
+557,799
New +$5.7M 0.07% 279

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return

Woodline Partners's HRTX Position: Q2 2023 in Review

Woodline Partners sold out of Heron Therapeutics (HRTX) in Q2 2023, closing a stake of 569,212 shares — an estimated $860K sold.

Woodline Partners first reported a position in HRTX in Q4 2021 and held it in 6 quarters. The position peaked at $5.09M in Q4 2021. 149 funds tracked by Wall St. Rank hold HRTX as of Q2 2023.

  • Woodline Partners reported no remaining Heron Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Woodline Partners sold 569,212 Heron Therapeutics shares in Q2 2023, an estimated $860K.
  • Woodline Partners first reported a position in Heron Therapeutics in Q4 2021 and held it in 6 quarters.
  • Woodline Partners's Heron Therapeutics position peaked at $5.09M in Q4 2021.
  • 149 funds tracked by Wall St. Rank held Heron Therapeutics as of Q2 2023.

Based on Woodline Partners's 13F filing for Q2 2023, filed 14 Aug 2023.